# Cognitive Dysfunction in MDD Patients

> **NCT03187093** · PHASE4 · UNKNOWN · sponsor: **Oleg Levada** · enrollment: 150 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Vortioxetine
- **DRUG:** Escitalopram

## Key facts

- **NCT ID:** NCT03187093
- **Lead sponsor:** Oleg Levada
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2019-04
- **Final completion:** 2019-04
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03187093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03187093, "Cognitive Dysfunction in MDD Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03187093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*